Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y, He H, Li X, Zhang L, Xu W, Feng R, Li W, Xiao Y, Liu X, Chen Y, Wang X, Bai B, Wu H, Cai Q, Li Z, Li J, Lin S, He Y, Ping L, Huang C, Mao J, Chen X, Zhao B, Huang H.
Gao Y, et al. Among authors: ping l.
Signal Transduct Target Ther. 2024 May 17;9(1):121. doi: 10.1038/s41392-024-01825-0.
Signal Transduct Target Ther. 2024.
PMID: 38755119
Free PMC article.
Clinical Trial.